ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1370

Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration

Eui-Jong Kwon1, Jin-Sil Park2, Ha Yeon Jeong3, Hye Yeon Kang4, JeongWon Choi3, Mi-La Cho3 and Sung-Hwan Park5, 1Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, 2The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, 3Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 4Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Meeting: ACR Convergence 2023

Keywords: Animal Model, B-Lymphocyte, Sjögren's syndrome, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction and dysfunctional glandular secretion. Metabolic abnormalities of immune cells infiltrated into the salivary gland of patients with SS induce abnormal cell death and hyperactivity, which is involved in the exacerbation of SS. In this study, we investigated the effects of HGR4113, a structural analogue of glabridin under clinical trial for obesity, that promotes mitochondrial function, on the development of Sjogren’s syndrome in non-obese diabetic NOD/ShiLtJ (NOD) mice.

Methods: NOD mice were orally administered 100 mg/kg of HGR4113 daily, and body weight, salivary flow rate, and blood glucose levels were measured every 3 weeks. Infiltration of inflammatory cells and levels of inflammation-related factors in salivary gland were histologically analyzed, and the development of salivary gland tissue organoids was investigated. The populations of various T– and B–cell subtypes in the spleen were assessed by flow cytometry. In vitro formation of salivary gland organoids was investigated by treatment with HGR4113.

Results: Oral administration of HGR4113 improved salivary flow rate and the infiltration of lymphocytes and the level of inflammatory cytokines in salivary gland of NOD mice. HGR4113 lowered the frequencies of splenic IL-17-producing T and B cells, germinal center B cells and plasma cells ex vivo in NOD mice. In addition, organoid formation from salivary gland stem cells of NOD mice administered with HGR4113 increased, and the levels of E-cadherin-14, Aquaporin-5, α-SMA, and Cytokeratin-14 increased. Treatment with HGR4113 also promoted the formation of salivary gland organoids in vitro.

Conclusion: These results show that HGR4113 can improve salivary gland hypofunction by inhibiting lymphocyte infiltration and inflammation in the salivary gland and restoring the damaged salivary gland in SS-Like NOD mice.

Supporting image 1

HGR4113 attenuates the severity of SS in NOD/ShiLtJ mice

Supporting image 2

Treatment with HGR4113 promotes the generation of salivary gland organoids in vitro

Supporting image 3

Treatment with HGR4113 regulates the frequency of inflammatory cells in humans


Disclosures: E. Kwon: None; J. Park: None; H. Jeong: None; H. Kang: None; J. Choi: None; M. Cho: None; S. Park: None.

To cite this abstract in AMA style:

Kwon E, Park J, Jeong H, Kang H, Choi J, Cho M, Park S. Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/synthetic-glabridin-derivatives-improves-sjogrens-syndrome-by-inducing-salivary-secretion-and-salivary-gland-regeneration/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synthetic-glabridin-derivatives-improves-sjogrens-syndrome-by-inducing-salivary-secretion-and-salivary-gland-regeneration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology